Literature DB >> 21213459

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

Debora Fumagalli1, Stefan Michiels, Christos Sotiriou.   

Abstract

Entities:  

Year:  2011        PMID： 21213459

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  2 in total

1.  Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.

Authors:  Silvia Cufi; Bruna Corominas-Faja; Alejandro Vazquez-Martin; Christina Oliveras-Ferraros; Joan Dorca; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Javier A Menendez
Journal:  Oncotarget       Date:  2012-04

2.  PPARγ maintains ERBB2-positive breast cancer stem cells.

Authors:  X Wang; Y Sun; J Wong; D S Conklin
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.